Table 2.
Cross-validation and hold-out test set performance metrics (AUC, accuracy, sensitivity, specificity) of networks CA (trained on Atrain) and CB (trained on Btrain) in detecting clinically significant prostate cancer slices, evaluated on three different b value settings (a) B4b900 (0, 300, 500, 900 s/mm2), (b) B4b2000 (0, 900, 1100, 2000 s/mm2), and (c) B2b1300 (0 and 1300 s/mm2). N = 112 patients scheduled for prostatectomy underwent two prostate MR examinations (SA and SB) performed on the same day approximately 15 min apart. The scans, SA and SB, were divided into training set (Atrain and Btrain), N = 78, and test set (Atest and Btest) N = 34
| b value setting | Cross-validation | AUC (95% CI) | Accuracy | Sensitivity | Specificity | p value (AUC) |
| B4b900 | CA | 0.81 (0.79–0.83) | 74% | 86% | 69% | p = 0.64 |
| CA | 0.82 (0.79–0.84) | 76% | 70% | 79% | ||
| B4b2000 | CA | 0.82 (0.79–0.84) | 78% | 69% | 82% | p = 0.18 |
| CB | 0.80 (0.78–0.83) | 71% | 77% | 69% | ||
| B2b1300 | CA | 0.85 (0.83–0.87) | 78% | 79% | 77% | p = 0.39 |
| CB | 0.84 (0.80–0.86) | 76% | 76% | 76% | ||
| b value setting | Hold-out test set (Stest) | AUC (95% CI) | Accuracy | Sensitivity | Specificity | p value (AUC) |
| B4b900 | CA | 0.78 (0.75–0.81) | 70% | 88% | 69% | p = 0.58 |
| CB | 0.79 (0.76–0.82) | 76% | 75% | 76% | ||
| B4b2000 | CA | 0.80 (0.77–0.84) | 76% | 81% | 74% | p = 0.11 |
| CB | 0.78 (0.75–0.82) | 74% | 74% | 73% | ||
| B2b1300 | CA | 0.84 (0.81–0.87) | 79% | 72% | 82% | p = 0.58 |
| CB | 0.85 (0.83–0.88) | 80% | 77% | 81% |